09:05 AM EDT, 10/07/2024 (MT Newswires) -- Akebia Therapeutics ( AKBA ) said Monday it entered into a multi-year commercial supply contract with U.S. Renal Care dialysis, or USRC, centers.

The contract allows USRC physicians to prescribe the company's drug, Vafseo, for dialysis patients when deemed clinically appropriate, with availability expected in January 2025.

Vafseo received US Food and Drug Administration approval in March 2024 for treating anemia due to chronic kidney disease in adults undergoing dialysis for at least three months.

Akebia expects to receive Transitional Drug Add-on Payment Adjustment designation for Vafseo in January 2025.

Price: 1.3494, Change: +0.02, Percent Change: +1.46